

Philipp T Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11983467/publications.pdf>

Version: 2024-02-01

125
papers

6,248
citations

101543

36
h-index

76900

74
g-index

127
all docs

127
docs citations

127
times ranked

8017
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
3	Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain, 2021, 144, 1263-1276.	7.6	245
4	Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. Journal of Neurology, 2013, 260, 2744-2753.	3.6	186
5	Sleep Deprivation Increases A1 Adenosine Receptor Binding in the Human Brain: A Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 2410-2415.	3.6	169
6	[¹⁸ F]FDG-PET is superior to [¹²³ I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology, 2012, 79, 1314-1322.	1.1	165
7	¹⁸ F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. Journal of Nuclear Medicine, 2017, 58, 1888-1898.	5.0	139
8	Comparison of ⁶⁸ Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	10.0	135
9	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
10	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
11	Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 2014, 4, 412-419.	10.0	127
12	Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics, 2017, 7, 1770-1780.	10.0	123
13	Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. Journal of Nuclear Medicine, 2021, 62, jnumed.121.262128.	5.0	108
14	⁶⁸ Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine, 2018, 59, 1406-1411.	5.0	106
15	A disease-specific metabolic brain network associated with corticobasal degeneration. Brain, 2014, 137, 3036-3046.	7.6	103
16	Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and ¹¹ C-Labeled Pittsburgh Compound B. Journal of Nuclear Medicine, 2011, 52, 393-400.	5.0	97
17	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
18	Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist ⁶⁸ Ga-RM2 And PET. Theranostics, 2016, 6, 1641-1650.	10.0	90

#	ARTICLE	IF	CITATIONS
19	In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. <i>NeuroImage</i> , 2003, 19, 1760-1769.	4.2	84
20	Caffeine Occupancy of Human Cerebral A ₁ Adenosine Receptors: In Vivo Quantification with ¹⁸ F-CPFPX and PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1723-1729.	5.0	74
21	Asymmetries of amyloid- β^2 burden and neuronal dysfunction are positively correlated in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3089-3099.	7.6	72
22	MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 889-897.	6.4	68
23	Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. <i>Neurobiology of Aging</i> , 2007, 28, 1914-1924.	3.1	63
24	Preoperative mapping of cortical language areas in adult brain tumour patients using PET and individual non-normalised SPM analyses. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 951-960.	6.4	62
25	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). <i>BMC Cancer</i> , 2016, 16, 769.	2.6	62
26	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	5.0	61
27	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. <i>Radiation Oncology</i> , 2018, 13, 81.	2.7	53
28	Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 948-954.	6.4	51
29	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1463-1472.	6.4	51
30	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. <i>Radiotherapy and Oncology</i> , 2017, 123, 472-477.	0.6	50
31	Principal Components Analysis of Brain Metabolism Predicts Development of Alzheimer Dementia. <i>Journal of Nuclear Medicine</i> , 2019, 60, 837-843.	5.0	50
32	(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. <i>PLoS ONE</i> , 2015, 10, e0145755.	2.5	46
33	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by ¹⁸ F-Fluoroethyl-L-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. <i>Journal of Nuclear Medicine</i> , 2017, 58, 129-137.	5.0	45
34	Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2015, 12, 2781-2790.	4.6	43
35	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. <i>Radiotherapy and Oncology</i> , 2019, 141, 208-213.	0.6	42
36	[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. <i>Pharmaceutics</i> , 2019, 12, 18.	3.8	41

#	ARTICLE	IF	CITATIONS
37	Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2022, 63, 971-980.	5.0	41
38	Localisation of motor areas in brain tumour patients: a comparison of preoperative [¹⁸ F]FDG-PET and intraoperative cortical electrostimulation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1394-1403.	2.1	39
39	Detection Rate of ¹⁸ F-Choline PET/CT and ⁶⁸ Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 971-977.	5.0	35
40	Quantification of Cerebral A1 Adenosine Receptors in Humans using [¹⁸ F]CPFPX and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 323-333.	4.3	33
41	Immuno-PET Imaging of CD30-Positive Lymphoma Using ⁸⁹ Zr-Desferrioxamine-Labelled CD30-Specific AC-10 Antibody. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96-102.	5.0	33
42	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. <i>Journal of Nuclear Medicine</i> , 2021, 62, 823-828.	5.0	32
43	Psychiatric Presentation of Anti-NMDA Receptor Encephalitis. <i>Frontiers in Neurology</i> , 2019, 10, 1086.	2.4	31
44	Predictive Value of ¹⁸ F-Florbetapir and ¹⁸ F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. <i>Journal of Nuclear Medicine</i> , 2020, 61, 597-603.	5.0	30
45	¹⁸ F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1541-1546.	5.0	29
46	Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 589-597.	6.4	28
47	Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. <i>Acta Oncologica</i> , 2016, 55, 1299-1304.	1.8	28
48	Hypercapnic BOLD MRI compared to H215O PET/CT for the hemodynamic evaluation of patients with Moyamoya Disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101713.	2.7	28
49	Metabolism of the A1 adenosine receptor PET ligand [¹⁸ F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. <i>Nuclear Medicine and Biology</i> , 2006, 33, 891-898.	0.6	27
50	Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 747-754.	0.9	27
51	Investigating dopaminergic neurotransmission with ¹²³ I-FP-CIT SPECT: comparability of modern SPECT systems. <i>Journal of Nuclear Medicine</i> , 2003, 44, 839-45.	5.0	27
52	Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. <i>Radiation Oncology</i> , 2018, 13, 159.	2.7	26
53	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2018, 13, 65.	2.7	26
54	Quantification of cerebral A1 adenosine receptors in humans using [¹⁸ F]CPFPX and PET: an equilibrium approach. <i>NeuroImage</i> , 2005, 24, 1192-1204.	4.2	25

#	ARTICLE	IF	CITATIONS
55	¹⁸ F-FDG PET Imaging of the Inferior Colliculus in Asymmetric Hearing Loss. <i>Journal of Nuclear Medicine</i> , 2020, 61, 418-422.	5.0	25
56	Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms. <i>Brain</i> , 2022, 145, 3203-3213.	7.6	25
57	Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 898-906.	2.2	24
58	Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake. <i>PLoS ONE</i> , 2017, 12, e0170435.	2.5	24
59	Image Quality and Data Quantification in Dopamine Transporter SPECT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 866-871.	1.3	23
60	Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease. <i>Behavioural Brain Research</i> , 2013, 239, 15-26.	2.2	23
61	Update on SPECT and PET in parkinsonism – part 1. <i>Current Opinion in Neurology</i> , 2014, 27, 390-397.	3.6	23
62	Neuropsychological impairment in adults with moyamoya angiopathy: preoperative assessment and correlation to MRI and H215O PET. <i>Neurosurgical Review</i> , 2020, 43, 1615-1622.	2.4	23
63	Simplified quantification of 5-HT _{2A} receptors in the human brain with [¹¹ C]MDL 100,907 PET and non-invasive kinetic analyses. <i>NeuroImage</i> , 2010, 50, 984-993.	4.2	21
64	Amyloid- β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1909-1914.	5.0	21
65	Preoperative mapping of cortical motor function: prospective comparison of functional magnetic resonance imaging and [¹⁵ O]-H ₂ O-positron emission tomography in the same co-ordinate system. <i>Nuclear Medicine Communications</i> , 2004, 25, 987-997.	1.1	20
66	A1 adenosine receptor PET using [¹⁸ F]CPFPX: Displacement studies in humans. <i>NeuroImage</i> , 2006, 32, 1100-1105.	4.2	20
67	Test-retest stability of cerebral A1 adenosine receptor quantification using [¹⁸ F]CPFPX and PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1061-1070.	6.4	20
68	Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1282-1288.	5.0	20
69	Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [¹⁸ F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 312-323.	6.4	20
70	Results from extended lymphadenectomies with [¹¹¹ In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. <i>EJNMMI Research</i> , 2020, 10, 17.	2.5	20
71	Estrogen Intake and Copper Depositions: Implications for Alzheimer's Disease. <i>Case Reports in Neurology</i> , 2014, 6, 181-187.	0.7	18
72	Voxel-wise deviations from healthy aging for the detection of region-specific atrophy. <i>NeuroImage: Clinical</i> , 2018, 20, 851-860.	2.7	18

#	ARTICLE	IF	CITATIONS
73	Accuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology. <i>Nuclear Medicine and Biology</i> , 2019, 70, 32-38.	0.6	18
74	Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach. <i>NeuroImage</i> , 2008, 42, 548-558.	4.2	17
75	Role of Semiquantitative Assessment of Regional Binding Potential in 123I-FP-CIT SPECT for the Differentiation of Frontotemporal Dementia, Dementia With Lewy Bodies, and Alzheimer's Dementia. <i>Clinical Nuclear Medicine</i> , 2015, 40, e27-e33.	1.3	16
76	Probable Autoimmune Catatonia With Antibodies Against Cilia on Hippocampal Granule Cells and Highly Suspicious Cerebral FDG-Positron Emission Tomography Findings. <i>Biological Psychiatry</i> , 2020, 87, e29-e31.	1.3	15
77	Deep Brain Stimulation of the Medial Forebrain Bundle in a Rodent Model of Depression: Exploring Dopaminergic Mechanisms with Raclopride and Micro-PET. <i>Stereotactic and Functional Neurosurgery</i> , 2020, 98, 8-20.	1.5	15
78	Update on SPECT and PET in parkinsonism – part 2. <i>Current Opinion in Neurology</i> , 2014, 27, 398-404.	3.6	14
79	Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. <i>Nuclear Medicine and Biology</i> , 2017, 45, 22-29.	0.6	14
80	Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1442-1448.	6.4	14
81	Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-l-Tyrosine PET. <i>Clinical Nuclear Medicine</i> , 2019, 44, 695-701.	1.3	14
82	Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>Clinical Nuclear Medicine</i> , 2020, 45, 283-287.	1.3	14
83	Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2062-2070.	6.4	13
84	Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. <i>EJNMMI Research</i> , 2019, 9, 37.	2.5	13
85	Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: Analyses based on venous blood sampling. <i>Synapse</i> , 2005, 55, 212-223.	1.2	12
86	Limits for Reduction of Acquisition Time and Administered Activity in ¹⁸ F-FDG PET Studies of Alzheimer Dementia and Frontotemporal Dementia. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1764-1770.	5.0	12
87	Psychiatric Manifestation of Anti-LGI1 Encephalitis. <i>Brain Sciences</i> , 2020, 10, 375.	2.3	12
88	Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1445-1459.	6.4	12
89	^{99m} Tc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. <i>EJNMMI Research</i> , 2021, 11, 22.	2.5	12
90	[18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1077-1080.	0.6	11

#	ARTICLE	IF	CITATIONS
91	Estimation of Severity of Moyamoya Disease with [15O]Water-Positron Emission Tomography Compared with Magnetic Resonance Imaging and Angiography. <i>World Neurosurgery</i> , 2018, 117, e75-e81.	1.3	11
92	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. <i>Neurology</i> , 2021, 96, e1358-e1368.	1.1	11
93	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. <i>Cancer Research</i> , 2021, 81, 2234-2245.	0.9	11
94	In vivo imaging of rat brain A 1 adenosine receptor occupancy by caffeine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1440-1440.	6.4	10
95	Cerebral kinetics of the dopamine D2 receptor ligand [123I]IBZM in mice. <i>Nuclear Medicine and Biology</i> , 2008, 35, 467-473.	0.6	10
96	Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice. <i>Nuclear Medicine and Biology</i> , 2008, 35, 543-548.	0.6	10
97	Regional neuronal activity in patients with relapsing remitting multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 466-474.	2.1	10
98	18F-CPFPX PET: on the generation of parametric images and the effect of scan duration. <i>Journal of Nuclear Medicine</i> , 2006, 47, 200-7.	5.0	10
99	Gastrin-Releasing Peptide Receptor Antagonist [68Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer. <i>Cancers</i> , 2021, 13, 6106.	3.7	10
100	Characterization of [¹²³ I]FPaCIT binding to the dopamine transporter in the striatum of tree shrews by quantitative <i>in vitro</i> autoradiography. <i>Synapse</i> , 2015, 69, 497-504.	1.2	9
101	Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 519-524.	1.3	9
102	123I-Iodobenzamide SPECT Is Not an Independent Predictor of Dopaminergic Responsiveness in Patients with Suspected Atypical Parkinsonian Syndromes. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2081-2086.	5.0	8
103	<i>Staphylococcus aureus</i> bacteremia with iliac artery endarteritis in a patient receiving ustekinumab. <i>BMC Infectious Diseases</i> , 2016, 16, 586.	2.9	8
104	Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study. <i>Journal of Neural Transmission</i> , 2018, 125, 995-1005.	2.8	8
105	Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. <i>Current Opinion in Neurology</i> , 2019, 32, 548-556.	3.6	8
106	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. <i>Npj Parkinson's Disease</i> , 2020, 6, 39.	5.3	8
107	Hemodynamic evaluation of patients with Moyamoya Angiopathy: comparison of resting-state fMRI to breath-hold fMRI and [15O]water PET. <i>Neuroradiology</i> , 2022, 64, 553-563.	2.2	8
108	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. <i>Future Oncology</i> , 2018, 14, 751-769.	2.4	7

#	ARTICLE	IF	CITATIONS
109	Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies. <i>Brain Sciences</i> , 2020, 10, 399.	2.3	7
110	Neural correlates of cognitive dysfunction in Lewy body diseases and tauopathies: Combined assessment with FDG-PET and the CERAD test battery. <i>Brain and Language</i> , 2013, 127, 307-314.	1.6	6
111	Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 855-860.	5.0	6
112	Novel Neuronal Autoantibodies in Huntington's Disease. <i>Biological Psychiatry</i> , 2022, 91, e21-e23.	1.3	6
113	Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 278-86.	1.0	6
114	Association between gastrin-releasing peptide receptor expression as assessed with [68Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer. <i>Nuclear Medicine and Biology</i> , 2020, 86-87, 37-43.	0.6	5
115	Brain activation patterns during visuomotor adaptation in motor experts and novices: An FDG PET study with unrestricted movements. <i>Journal of Neuroscience Methods</i> , 2021, 350, 109061.	2.5	5
116	Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1558-1564.	5.0	3
117	Reply: From early limbic inflammation to long COVID sequelae. <i>Brain</i> , 2021, 144, e66-e66.	7.6	3
118	[123I]FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: A Data-Driven Analysis. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1457-1465.	2.8	2
119	Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to [123I]FP-CIT SPECT and [18F]FDG PET. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1721-1729.	2.6	2
120	PET/CT background noise and its effect on speech recognition. <i>Scientific Reports</i> , 2021, 11, 22065.	3.3	2
121	Preoperative brain mapping using [15O]water activation PET provides evidence on altered language networks in an adult brain tumour patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1705-1705.	6.4	1
122	Positron Emission Tomography Imaging in Human Immunodeficiency Virus-1-Associated Neurocognitive Disorders. <i>Clinical Nuclear Medicine</i> , 2009, 34, 496-499.	1.3	1
123	Neural activity of the auditory cortex predicts speech recognition of patients with asymmetric hearing loss after cochlear implantation. <i>Scientific Reports</i> , 2022, 12, 8068.	3.3	1
124	Metabolic patterns associated with survival in PSP/CBS: An 18FDG PET voxel-based analysis. <i>Basal Ganglia</i> , 2016, 6, 45-51.	0.3	0
125	Impact of sleep deprivation on cerebral A1 adenosine receptor (A1AR) density: A PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S316-S316.	4.3	0